Pathophysiology and prevention of methotrexate chemotherapy-induced bone growth defects

甲氨蝶呤化疗引起的骨生长缺陷的病理生理学和预防

• 批准号: nhmrc : 508046
• 负责人: A/Pr Bruce Foster
• 金额: $ 41.51万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/pathophysiology-prevention-methotrexate-growth-defects/96068
• 关键词: Pathophysiology; prevention; methotrexate; chemotherapy; induced

Childhood chemotherapy often causes growth arrest, osteoporosis, and fractures in cancer patients and survivors. Using a rat model, this project will study how the most commonly used chemotherapy drug methotrexate causes bone growth defects and examine any protective effects of two natural-derived substances. This work will increase our knowledge on chemotherapy-induced bone growth defects, and will be useful for developing a preventative treatment.

儿童期化疗常常导致癌症患者和幸存者的生长停滞、骨质疏松和骨折。使用大鼠模型，该项目将研究最常用的化疗药物甲氨蝶呤如何导致骨生长缺陷，并检查两种天然衍生物质的任何保护作用。这项工作将增加我们对化疗引起的骨生长缺陷的认识，并将有助于开发预防性治疗。